ClinicalTrials.gg
CompletedNCT01026818REACTTUpdated Jan 14, 2014Results posted

A Study of Tadalafil After Radical Prostatectomy

A Phase 4 interventional study of Tadalafil and Placebo in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 52 sites in 10 countries. Open to male participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2014-01-14.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
583
Allocation
Randomized
Ages
18 Years to 67 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.

Enrollment
10th of 56
583 · median 199
Started
2009
with 4 others
Phase 4
26 of 57
3 open now
Registered
25th of 57
by date
Lead sponsor
26 of 57
Eli Lilly and Company

Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 10th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2009, is one of 26 in phase 4, and was the 25th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 67 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing tadalafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

The study will include patients with localized prostate cancer who experience erectile dysfunction following bilateral nerve-sparing radical prostatectomy. Patients will be randomly assigned to three treatment arms: Tadalafil 5 mg once a day, Tadalafil 20 mg on demand (prior to anticipated sexual activity), and placebo. Patients will stay on therapy for 9 months and after withdrawal of medication for 6 weeks, patients will be evaluated for recovery of unassisted erectile function (without medication). An open-label extension for three months will evaluate the responsiveness of all patients to Tadalafil 5 mg once a day. Further objectives are to evaluate the treatment satisfaction of the respective therapies.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

Keywords

  • Erectile Dysfunction
  • Radical Prostatectomy
04

Who can participate

Ages eligible
18 Years to 67 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • scheduled to undergo Bilateral nerve-sparing radical prostatectomy (BNSRP) for organ-confined, non- prostate cancer
  • have a normal preoperative erectile function score of more or equal to 22 at screening(as evaluated by International Index of Erectile Function - Erectile Function domain (IIEF-EF))
  • develop Erectile Dysfunction (ED) (defined as the consistent inability to achieve and/or maintain an erection sufficient to permit satisfactory sexual intercourse) after surgery
  • have an interest in resuming sexual activity as soon as possible after surgery and anticipate having the same adult female sexual partner during the study
  • agree not to use any other treatment for ED, including herbal and over-the-counter (OTC) medications, during the study
  • does not require the initiation of therapy for prostate cancer

Exclusion criteria

Exclusion Criteria:

  • history of ED
  • have received previous or current treatment with tadalafil or any other Phosphodiesterase Type 5 (PDE5) inhibitor
  • have undergone, or plan to undergo, radiation or hormonal therapy for prostate cancer
  • have a history of prostatic surgery or prostatic physical treatments
  • have a history of diabetes mellitus
  • have a history of galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption
  • have renal insufficiency as determined by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
583 participants (actual)

Study arms

  • Experimental
    Tadalafil daily [5 milligrams (mg)]

    After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.

    Drug: Tadalafil

  • Experimental
    Tadalafil on demand (20 mg)

    After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.

    Drug: Tadalafil

  • Placebo comparator
    Placebo

    After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.

    Drug: Placebo

Interventions

  • Administered by mouth for 9 months

    Also known as: Cialis, LY450190

  • DrugPlacebo

    Administered by mouth, daily or on demand for 9 months

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Score of Greater Than or Equal to 22 in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire

    Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.

    Time frame: Month 10.5

Secondary outcomes

  1. Percentage of Participants With a Score of Greater Than or Equal to 22 in the International Index of Erectile Function- Erectile Function (IIEF-EF) Domain

    Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.

    Time frame: Month 9 and Month 13.5

  2. Change From Baseline to Endpoint in the International Index of Erectile Function- Erectile Function (IIEF-EF) Total Score

    Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).

    Time frame: Randomization (Baseline), Months 9 and 10.5 and 13.5

  3. Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF) Domains (Intercourse Satisfaction Domain, Orgasmic Function Domain, Sexual Desire Domain, Overall Satisfaction Domain)

    Self-reported overall satisfaction during past 4 weeks. Orgasmic function score is sum of Questions (Q)9 and 10 of IIEF. Scores range from 0 (no sexual stimulation or intercourse) to 5 (high orgasm) for each Q, total 0 to 10. Sexual desire score is sum of Q11 and 12 of IIEF. Scores range from 1 (low/no desire) to 5 (high desire) for each Q, total 2 to 10. Intercourse satisfaction score is sum of Q6, 7 and 8 of IIEF. Scores range from 0 (no attempts for Q6, did not attempt intercourse for Q7 and no intercourse for Q8) to 5 (high satisfaction) for each Q, total 0 to 15. Overall satisfaction score is sum of Q13 and 14 of IIEF. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each Q, total 2 to 10. Higher total scores for each domain indicate higher function. MMRM analysis was used to calculate LS mean and 95% CI. LS mean values are adjusted for baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).

    Time frame: Randomization (Baseline), Months 9 and 10.5 and 13.5

  4. Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire Mean Score

    The EDITS questionnaire is a validated questionnaire consisting of 11 questions evaluating self-reported satisfaction with the erectile dysfunction (ED) treatment. Responses were based on the experiences during the previous 4 weeks. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS mean score was obtained by adding each individual result for all questions, dividing by the number of questions answered. The mean scores range from 0 (extremely low treatment satisfaction) to 4 (extremely high satisfaction). The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).

    Time frame: Months 9 and 13.5

  5. Change From Baseline in Self Esteem and Relationship (SEAR) Questionnaire Score

    The SEAR questionnaire is a participant-reported measure of psychosocial outcomes in men with erectile dysfunction (ED). It consists of 14 items. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The total scores for sexual relationship domain range from 8-40 with higher scores indicating better relationship. Self-Esteem subdomain contains items 9 through 12 rated on a scale of 1 (no/low self-esteem) to 5 (high self-esteem). Total scores for Self-Esteem subscale range from 4-20 with higher scores indicating higher self-esteem. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).

    Time frame: Randomization (Baseline), Months 9 and 13.5

  6. Global Assessment Questions (GAQ) Question 1 at Month 9

    GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).

    Time frame: Month 9

  7. Global Assessment Question (GAQ) Question 1 at Month 13.5

    GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).

    Time frame: Month 13.5

  8. Global Assessment Question (GAQ) Question 2 at Month 9

    GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).

    Time frame: Month 9

  9. Global Assessment Question (GAQ) Question 2 at Month 13.5

    GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).

    Time frame: Month 13.5

  10. Residual Erectile Function (REF) at Baseline

    The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)

    Time frame: Baseline

  11. Residual Erectile Function (REF) at Month 2

    The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)

    Time frame: Month 2

  12. Residual Erectile Function (REF) at Month 5

    The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)

    Time frame: Month 5

  13. Residual Erectile Function (REF) at Month 9

    The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)

    Time frame: Month 9

  14. Residual Erectile Function (REF) at Month 10.5

    The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)

    Time frame: Month 10.5

  15. Residual Erectile Function (REF) at Month 13.5

    The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)

    Time frame: Month 13.5

  16. Change From Baseline in 'Yes' Answers to Questions 1 to 5 of the Sexual Encounter Profile (SEP)

    Participant-assessed diary has 5 questions: Question (Q)1: erection achievement, Q2: successful penetration, Q3: successful intercourse, Q4: satisfied with erection, and Q5: satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1-Q5 scores were determined as the percentage of 'Yes' responses to each of the 5 questions out of all sexual attempts recorded during the time period. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).

    Time frame: Randomization (Baseline), Months 9 and 10.5 and 13.5

  17. Change From Baseline in 'Yes' Answers to Morning Erections

    The participants were asked to complete the morning erections diary every morning during the 4-week period before randomization and during the 6-week, Drug-Free, Washout Period. Data presented are the changes in the participant's percentage of "yes" responses relative to the number of days the question was answered during treatment. The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline morning erections frequency, age group and country.

    Time frame: Randomization (Baseline), Month 10.5

  18. Standardized Morning Erections Question (SMEQ) Score at Month 2

    Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ ("Do you ever wake up with an erection") using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).

    Time frame: Month 2

  19. Standardized Morning Erections Question (SMEQ) Score at Month 9

    Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ ("Do you ever wake up with an erection") using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).

    Time frame: Month 9

  20. Standardized Morning Erections Question (SMEQ) Score at Month 13.5

    Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ ("Do you ever wake up with an erection") using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).

    Time frame: Month 13.5

  21. Change From Baseline in 26-item Expanded Prostate Cancer Index Composite (EPIC-26) Questionnaire Score

    EPIC-26 (participants) contains 26 items and 5 domains: Urinary Incontinence (Items 1-4), Urinary Irritative/Obstructive (Items 5-8), Bowel (Items 10-15), Sexual (Items 16-21), and Hormonal (Items 22-26). Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0 to 100 scale for each domain, with higher scores representing better health-related quality of life. Responses are based on experiences during the previous 4 weeks. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).

    Time frame: Randomization (Baseline), Months 9 and 13.5

  22. Change in Penile Length and Girth

    Measurements were performed with the penis in the flaccid state. The stretched penile length was measured from the tip of the glans to the pubopenile skin junction while applying tension to maximally stretch the penis. The penile circumference at midshaft was measured. All measurements were taken with a paper ruler to the nearest 0.5 centimeter (cm). The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline, age group and country.

    Time frame: Randomization (Baseline), Month 9

07

Results

Posted Nov 14, 2013

Participant flow

Screening Period
Participant flow — Screening Period
MilestoneScreen - BNSRPTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Started583000
Completed423000
Not completed160000
Withdrew: Entry criteria not met105000
Withdrew: Withdrawal by subject49000
Withdrew: Protocol deviation3000
Withdrew: Adverse event2000
Withdrew: Physician decision1000
DB Treatment Period (Month 0 - 9)
Participant flow — DB Treatment Period (Month 0 - 9)
MilestoneScreen - BNSRPTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Started0139143141
Received at least 1 dose of study drug0139143141
Completed0114122115
Not completed0252126
Withdrew: Adverse event01064
Withdrew: Withdrawal by subject0733
Withdrew: Lack of efficacy0326
Withdrew: Lost to follow-up0304
Withdrew: Entry criteria not met0297
Withdrew: Protocol deviation0012
Drug-Free Washout Period (Month 9-10.5)
Participant flow — Drug-Free Washout Period (Month 9-10.5)
MilestoneScreen - BNSRPTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Started0114122115
Completed0105117108
Not completed0957
Withdrew: Entry criteria not met0212
Withdrew: Lack of efficacy0212
Withdrew: Adverse event0100
Withdrew: Lost to follow-up0102
Withdrew: Physician decision0110
Withdrew: Sponsor decision0100
Withdrew: Withdrawal by subject0120
Withdrew: Death0001
OL Period (Month 10.5 - 13.5)
Participant flow — OL Period (Month 10.5 - 13.5)
MilestoneScreen - BNSRPTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Started0105117108
Completed098112105
Not completed0753
Withdrew: Entry criteria not met0200
Withdrew: Lack of efficacy0100
Withdrew: Lost to follow-up0121
Withdrew: Protocol deviation0131
Withdrew: Withdrawal by subject0201

Outcome measures

PrimaryPercentage of Participants With a Score of Greater Than or Equal to 22 in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire

Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.

Time frame:
Month 10.5
Reported as:
Number · percentage of participants
Percentage of Participants With a Score of Greater Than or Equal to 22 in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire
percentage of participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Percentage of Participants With a Score of Greater Than or Equal to 22 in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire20.916.919.1
Statistical analysis
  • Tadalafil 5 mg OaD vs Placebo · Regression, Logistic · p = 0.675 (The Type I error was controlled for multiplicity using a Bonferroni-Hommel procedure. First the largest p-value for the odds ratio to placebo was tested at the 5% level and in case of no rejection the second p-value was tested at the 2.5% level.) · Odds ratio (or): 1.14 · 95% CI 0.63 to 2.06The logistic regression model included terms for treatment group, country, and age group.
  • Tadalafil 20 mg PRN vs Placebo · Regression, Logistic · p = 0.704 (The Type I error was controlled for multiplicity using a Bonferroni-Hommel procedure. First the largest p-value for the odds ratio to placebo was tested at the 5% level and in case of no rejection the second p-value was tested at the 2.5% level.) · Odds ratio (or): 0.89 · 95% CI 0.48 to 1.65The logistic regression model included terms for treatment group, country, and age group.
SecondaryPercentage of Participants With a Score of Greater Than or Equal to 22 in the International Index of Erectile Function- Erectile Function (IIEF-EF) Domain

Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.

Time frame:
Month 9 and Month 13.5
Reported as:
Number · percentage of participants
Percentage of Participants With a Score of Greater Than or Equal to 22 in the International Index of Erectile Function- Erectile Function (IIEF-EF) Domain
percentage of participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Month 925.219.714.2
Month 13.532.433.127.0
Statistical analysis
  • Tadalafil 5 mg OaD vs Placebo · Regression, Logistic · p = 0.016 (P-value is for Month 9.) · Odds ratio (or): 2.15 · 95% CI 1.16 to 3.99The logistic regression model included terms for treatment group, country, and age group.
  • Tadalafil 20 mg PRN vs Placebo · Regression, Logistic · p = 0.210 (P-value is for Month 9.) · Odds ratio (or): 1.50 · 95% CI 0.79 to 2.85The logistic regression model included terms for treatment group, country, and age group.
  • Tadalafil 5 mg OaD vs Placebo · Regression, Logistic · p = 0.273 (P-value is for Month 13.5.) · Odds ratio (or): 1.34 · 95% CI 0.79 to 2.28The logistic regression model included terms for treatment group, country, and age group.
  • Tadalafil 20 mg PRN vs Placebo · Regression, Logistic · p = 0.259 (P-value is for Month 13.5.) · Odds ratio (or): 1.35 · 95% CI 0.80 to 2.29The logistic regression model included terms for treatment group, country, and age group.
SecondaryChange From Baseline to Endpoint in the International Index of Erectile Function- Erectile Function (IIEF-EF) Total Score

Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).

Time frame:
Randomization (Baseline), Months 9 and 10.5 and 13.5
Reported as:
Least squares mean · units on a scale
Change From Baseline to Endpoint in the International Index of Erectile Function- Erectile Function (IIEF-EF) Total Score
units on a scaleTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Month 97.73 (5.73 to 9.73)6.53 (4.56 to 8.50)4.93 (2.88 to 6.98)
Month 10.56.24 (4.22 to 8.25)5.76 (3.78 to 7.73)5.98 (3.92 to 8.03)
Month 13.510.60 (8.39 to 12.80)9.78 (7.63 to 11.92)8.97 (6.74 to 11.21)
Statistical analysis
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.007 (P-value is for Month 9.) · Ls mean differences: 2.80 · 95% CI 0.76 to 4.83The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.118 (P-value is for Month 9.) · Ls mean differences: 1.59 · 95% CI -0.41 to 3.60The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.802 (P-value is for Month 10.5.) · Ls mean differences: 0.26 · 95% CI -1.79 to 2.31The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.830 (P-value is for Month 10.5.) · Ls mean differences: -0.22 · 95% CI -2.23 to 1.79The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.184 (P-value is for Month 13.5.) · Ls mean differences: 1.62 · 95% CI -0.78 to 4.03The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.500 (P-value is for Month 13.5.) · Ls mean differences: 0.81 · 95% CI -1.54 to 3.16The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
SecondaryChange From Baseline to Endpoint in the International Index of Erectile Function (IIEF) Domains (Intercourse Satisfaction Domain, Orgasmic Function Domain, Sexual Desire Domain, Overall Satisfaction Domain)

Self-reported overall satisfaction during past 4 weeks. Orgasmic function score is sum of Questions (Q)9 and 10 of IIEF. Scores range from 0 (no sexual stimulation or intercourse) to 5 (high orgasm) for each Q, total 0 to 10. Sexual desire score is sum of Q11 and 12 of IIEF. Scores range from 1 (low/no desire) to 5 (high desire) for each Q, total 2 to 10. Intercourse satisfaction score is sum of Q6, 7 and 8 of IIEF. Scores range from 0 (no attempts for Q6, did not attempt intercourse for Q7 and no intercourse for Q8) to 5 (high satisfaction) for each Q, total 0 to 15. Overall satisfaction score is sum of Q13 and 14 of IIEF. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each Q, total 2 to 10. Higher total scores for each domain indicate higher function. MMRM analysis was used to calculate LS mean and 95% CI. LS mean values are adjusted for baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).

Time frame:
Randomization (Baseline), Months 9 and 10.5 and 13.5
Reported as:
Least squares mean · units on a scale
Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF) Domains (Intercourse Satisfaction Domain, Orgasmic Function Domain, Sexual Desire Domain, Overall Satisfaction Domain)
units on a scaleTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Orgasmic function - Month 92.76 (1.98 to 3.55)2.48 (1.70 to 3.26)2.39 (1.59 to 3.19)
Orgasmic function - Month 10.52.94 (2.13 to 3.76)2.48 (1.68 to 3.28)2.48 (1.66 to 3.31)
Orgasmic function - Month 13.53.57 (2.75 to 4.39)2.90 (2.10 to 3.70)3.42 (2.59 to 4.25)
Sexual desire - Month 90.65 (0.18 to 1.12)0.65 (0.18 to 1.11)0.63 (0.15 to 1.11)
Sexual desire - Month 10.50.61 (0.14 to 1.07)0.65 (0.20 to 1.11)0.55 (0.08 to 1.01)
Sexual desire - Month 13.51.04 (0.56 to 1.52)0.89 (0.42 to 1.35)0.95 (0.46 to 1.43)
Intercourse satisfaction - Month 93.89 (2.90 to 4.88)3.50 (2.52 to 4.48)2.96 (1.95 to 3.96)
Intercourse satisfaction - Month 10.53.21 (2.19 to 4.22)2.81 (1.81 to 3.81)2.72 (1.69 to 3.75)
Intercourse satisfaction - Month 13.54.70 (3.65 to 5.75)4.08 (3.05 to 5.10)4.14 (3.08 to 5.20)
Overall satisfaction - Month 90.97 (0.38 to 1.56)0.93 (0.35 to 1.51)0.78 (0.18 to 1.38)
Overall satisfaction - Month 10.50.64 (0.05 to 1.23)0.48 (-0.10 to 1.06)0.72 (0.12 to 1.32)
Overall satisfaction - Month 13.51.50 (0.87 to 2.13)1.57 (0.96 to 2.19)1.52 (0.88 to 2.15)
Statistical analysis
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.340 (P-value is for orgasmic function - Month 9.) · Ls mean differences: 0.37 · 95% CI -0.39 to 1.14The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.821 (P-value is for orgasmic function - Month 9.) · Ls mean differences: 0.09 · 95% CI -0.67 to 0.84The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.268 (P-value is for orgasmic function - Month 10.5.) · Ls mean differences: 0.46 · 95% CI -0.36 to 1.28The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.998 (P-value is for orgasmic function - Month 10.5.) · Ls mean differences: -0.00 · 95% CI -0.80 to 0.80The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.728 (P-value is for orgasmic function - Month 13.5.) · Ls mean differences: 0.15 · 95% CI -0.68 to 0.97The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.203 (P-value is for orgasmic function - Month 13.5.) · Ls mean differences: -0.52 · 95% CI -1.33 to 0.28The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.950 (P-value is for sexual desire - Month 9.) · Ls mean differences: 0.02 · 95% CI -0.46 to 0.49The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.950 (P-value is for sexual desire - Month 9.) · Ls mean differences: 0.01 · 95% CI -0.45 to 0.48The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.792 (P-value is for sexual desire - Month 10.5.) · Ls mean differences: 0.06 · 95% CI -0.39 to 0.51The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.631 (P-value is for sexual desire - Month 10.5.) · Ls mean differences: 0.11 · 95% CI -0.34 to 0.55The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.691 (P-value is for sexual desire - Month 13.5.) · Ls mean differences: 0.10 · 95% CI -0.38 to 0.58The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.801 (P-value is for sexual desire - Month 13.5.) · Ls mean differences: -0.06 · 95% CI -0.53 to 0.41The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.065 (P-value is for intercourse satisfaction - Month 9.) · Ls mean differences: 0.93 · 95% CI -0.06 to 1.92The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.274 (P-value is for intercourse satisfaction - Month 9.) · Ls mean differences: 0.54 · 95% CI -0.43 to 1.51The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.359 (P-value is for intercourse satisfaction - Month 10.5.) · Ls mean differences: 0.48 · 95% CI -0.55 to 1.52The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.863 (P-value is for intercourse satisfaction - Month 10.5.) · Ls mean differences: 0.09 · 95% CI -0.93 to 1.11The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.314 (P-value is for intercourse satisfaction - Month 13.5.) · Ls mean differences: 0.56 · 95% CI -0.53 to 1.66The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.910 (P-value is for intercourse satisfaction - Month 13.5.) · Ls mean differences: -0.06 · 95% CI -1.13 to 1.01The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.532 (P-value is for overall satisfaction - Month 9.) · Ls mean differences: 0.19 · 95% CI -0.40 to 0.78The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.620 (P-value is for overall satisfaction - Month 9.) · Ls mean differences: 0.15 · 95% CI -0.43 to 0.73The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.792 (P-value is for overall satisfaction - Month 10.5.) · Ls mean differences: -0.08 · 95% CI -0.67 to 0.51The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.410 (P-value is for overall satisfaction - Month 10.5.) · Ls mean differences: -0.24 · 95% CI -0.82 to 0.34The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.955 (P-value is for overall satisfaction - Month 13.5.) · Ls mean differences: -0.02 · 95% CI -0.68 to 0.65The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.868 (P-value is for overall satisfaction - Month 13.5.) · Ls mean differences: 0.05 · 95% CI -0.59 to 0.70The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
SecondaryErectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire Mean Score

The EDITS questionnaire is a validated questionnaire consisting of 11 questions evaluating self-reported satisfaction with the erectile dysfunction (ED) treatment. Responses were based on the experiences during the previous 4 weeks. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS mean score was obtained by adding each individual result for all questions, dividing by the number of questions answered. The mean scores range from 0 (extremely low treatment satisfaction) to 4 (extremely high satisfaction). The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).

Time frame:
Months 9 and 13.5
Reported as:
Least squares mean · units on a scale
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire Mean Score
units on a scaleTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Month 92.21 ± 0.112.11 (1.92 to 2.30)1.88 (1.67 to 2.09)
Month 13.52.54 (2.31 to 2.77)2.38 (2.17 to 2.59)2.25 (2.03 to 2.48)
Statistical analysis
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.005 (P-value is for Month 9.) · Ls mean differences: 0.33 · 95% CI 0.10 to 0.56The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.041 (P-value is for Month 9.) · Ls mean differences: 0.23 · 95% CI 0.01 to 0.45The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.035 (P-value is for Month 13.5.) · Ls mean differences: 0.28 · 95% CI 0.02 to 0.54The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.316 (P-value is for Month 13.5.) · Ls mean differences: 0.13 · 95% CI -0.12 to 0.38The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
SecondaryChange From Baseline in Self Esteem and Relationship (SEAR) Questionnaire Score

The SEAR questionnaire is a participant-reported measure of psychosocial outcomes in men with erectile dysfunction (ED). It consists of 14 items. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The total scores for sexual relationship domain range from 8-40 with higher scores indicating better relationship. Self-Esteem subdomain contains items 9 through 12 rated on a scale of 1 (no/low self-esteem) to 5 (high self-esteem). Total scores for Self-Esteem subscale range from 4-20 with higher scores indicating higher self-esteem. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).

Time frame:
Randomization (Baseline), Months 9 and 13.5
Reported as:
Least squares mean · units on a scale
Change From Baseline in Self Esteem and Relationship (SEAR) Questionnaire Score
units on a scaleTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Sexual relationship - Month 94.78 (2.87 to 6.68)3.50 (1.61 to 5.38)3.02 (1.09 to 4.95)
Sexual relationship - Month 13.56.90 (4.79 to 9.00)6.68 (4.62 to 8.74)6.72 (4.62 to 8.83)
Self-esteem - Month 90.78 (-0.31 to 1.87)0.79 (-0.29 to 1.87)0.51 (-0.61 to 1.62)
Self-esteem - Month 13.51.67 (0.54 to 2.81)1.72 (0.61 to 2.83)1.62 (0.47 to 2.77)
Statistical analysis
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.086 (P-value is for sexual relationship - Month 9.) · Ls mean differences: 1.75 · 95% CI -0.25 to 3.76The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.637 (P-value is for sexual relationship - Month 9.) · Ls mean differences: 0.47 · 95% CI -1.50 to 2.45The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.885 (P-value is for sexual relationship - Month 13.5) · Ls mean differences: 0.17 · 95% CI -2.18 to 2.53The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.972 (P-value is for sexual relationship - Month 13.5.) · Ls mean differences: -0.04 · 95% CI -2.34 to 2.25The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.621 (P-value is for self-esteem - Month 9.) · Ls mean differences: 0.27 · 95% CI -0.81 to 1.36The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.598 (P-value is for self-esteem - Month 9.) · Ls mean differences: 0.29 · 95% CI -0.78 to 1.35The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.923 (P-value is for self-esteem - Month 13.5.) · Ls mean differences: 0.06 · 95% CI -1.10 to 1.21The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.857 (P-value is for self-esteem - Month 13.5.) · Ls mean differences: 0.10 · 95% CI -1.03 to 1.24The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
SecondaryGlobal Assessment Questions (GAQ) Question 1 at Month 9

GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).

Time frame:
Month 9
Reported as:
Number · participants
Global Assessment Questions (GAQ) Question 1 at Month 9
participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Very much better9104
Much better12229
A little better333222
No change312848
A little worse453
Much worse686
Very much worse81114
Missing1169
SecondaryGlobal Assessment Question (GAQ) Question 1 at Month 13.5

GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).

Time frame:
Month 13.5
Reported as:
Number · participants
Global Assessment Question (GAQ) Question 1 at Month 13.5
participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Very much better131916
Much better242518
A little Better282728
No Change192326
A little worse442
Much worse335
Very much worse566
Missing475
SecondaryGlobal Assessment Question (GAQ) Question 2 at Month 9

GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).

Time frame:
Month 9
Reported as:
Number · participants
Global Assessment Question (GAQ) Question 2 at Month 9
participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Very much better773
Much better122511
A little better302618
No change312749
A little worse8104
Much worse71010
Very much worse9911
Missing1089
SecondaryGlobal Assessment Question (GAQ) Question 2 at Month 13.5

GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).

Time frame:
Month 13.5
Reported as:
Number · participants
Global Assessment Question (GAQ) Question 2 at Month 13.5
participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Very much better92014
Much better292321
A little better202624
No change252426
A little worse455
Much worse437
Very much worse564
Missing475
SecondaryResidual Erectile Function (REF) at Baseline

The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)

Time frame:
Baseline
Reported as:
Number · participants
Residual Erectile Function (REF) at Baseline
participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
REF = 0616264
REF = 1464847
REF = 2181717
REF = 3121113
REF = 4020
Missing220
SecondaryResidual Erectile Function (REF) at Month 2

The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)

Time frame:
Month 2
Reported as:
Number · participants
Residual Erectile Function (REF) at Month 2
participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
REF = 0282738
REF = 1385153
REF = 2262819
REF = 3252315
REF = 4955
Missing13811
SecondaryResidual Erectile Function (REF) at Month 5

The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)

Time frame:
Month 5
Reported as:
Number · participants
Residual Erectile Function (REF) at Month 5
participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
REF = 0122127
REF = 1373935
REF = 2192127
REF = 3323419
REF = 41566
Missing879
SecondaryResidual Erectile Function (REF) at Month 9

The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)

Time frame:
Month 9
Reported as:
Number · participants
Residual Erectile Function (REF) at Month 9
participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
REF = 0111723
REF = 1252835
REF = 2223023
REF = 3232718
REF = 4201510
Missing1356
SecondaryResidual Erectile Function (REF) at Month 10.5

The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)

Time frame:
Month 10.5
Reported as:
Number · participants
Residual Erectile Function (REF) at Month 10.5
participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
REF = 0131722
REF = 1293029
REF = 2252319
REF = 3223122
REF = 4121014
Missing462
SecondaryResidual Erectile Function (REF) at Month 13.5

The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)

Time frame:
Month 13.5
Reported as:
Number · participants
Residual Erectile Function (REF) at Month 13.5
participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
REF = 05811
REF = 1192025
REF = 2172015
REF = 3343428
REF = 4212824
Missing443
SecondaryChange From Baseline in 'Yes' Answers to Questions 1 to 5 of the Sexual Encounter Profile (SEP)

Participant-assessed diary has 5 questions: Question (Q)1: erection achievement, Q2: successful penetration, Q3: successful intercourse, Q4: satisfied with erection, and Q5: satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1-Q5 scores were determined as the percentage of 'Yes' responses to each of the 5 questions out of all sexual attempts recorded during the time period. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).

Time frame:
Randomization (Baseline), Months 9 and 10.5 and 13.5
Reported as:
Least squares mean · percentage of "yes" responses
Change From Baseline in 'Yes' Answers to Questions 1 to 5 of the Sexual Encounter Profile (SEP)
percentage of "yes" responsesTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Q1 - Month 967.41 (58.29 to 76.54)63.88 (55.32 to 72.44)52.54 (43.62 to 61.46)
Q1 - Month 10.567.78 (58.05 to 77.50)64.24 (55.06 to 73.41)58.86 (49.15 to 68.58)
Q1 - Month 13.586.16 (77.82 to 94.51)79.79 (71.93 to 87.65)75.27 (66.93 to 83.60)
Q2 - Month 944.00 (35.22 to 52.78)34.29 (26.03 to 42.56)27.67 (19.11 to 36.23)
Q2 - Month 10.540.81 (31.21 to 50.40)34.99 (25.91 to 44.08)36.26 (26.67 to 45.85)
Q2 - Month 13.563.48 (53.87 to 73.09)56.07 (46.91 to 65.24)50.11 (40.56 to 59.67)
Q3 - Month 933.67 (25.47 to 41.86)24.09 (16.36 to 31.82)21.61 (13.62 to 29.59)
Q3 - Month 10.528.75 (19.92 to 37.57)23.01 (14.65 to 31.37)28.52 (19.68 to 37.36)
Q3 - Month 13.552.41 (42.80 to 62.02)45.83 (36.63 to 55.04)40.75 (31.18 to 50.31)
Q4 - Month 926.17 (18.93 to 33.40)18.15 (11.31 to 24.99)14.30 (7.25 to 21.35)
Q4 - Month 10.516.94 (9.66 to 24.23)11.74 (4.84 to 18.64)18.88 (11.54 to 26.22)
Q4 - Month 13.542.08 (32.99 to 51.18)35.62 (26.88 to 44.37)30.56 (21.48 to 39.65)
Q5 - Month 925.42 (18.29 to 32.55)17.73 (10.99 to 24.47)14.04 (7.09 to 20.99)
Q5 - Month 10.516.26 (9.21 to 23.31)10.52 (3.85 to 17.19)19.11 (12.00 to 26.23)
Q5 - Month 13.540.81 (31.82 to 49.81)34.96 (26.31 to 43.62)29.38 (20.39 to 38.37)
Statistical analysis
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.008 (P-value is for Q1 - Month 9.) · Ls mean differences: 14.87 · 95% CI 3.92 to 25.83The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.038 (P-value is for Q1 - Month 9.) · Ls mean differences: 11.34 · 95% CI 0.63 to 22.04The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.148 (P-value is for Q1 - Month 10.5.) · Ls mean differences: 8.91 · 95% CI -3.18 to 21.00The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.373 (P-value is for Q1 - Month 10.5.) · Ls mean differences: 5.37 · 95% CI -6.48 to 17.23The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.029 (P-value is for Q1 - Month 13.5.) · Ls mean differences: 10.90 · 95% CI 1.14 to 20.66The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.357 (P-value is for Q1 - Month 13.5.) · Ls mean differences: 4.53 · 95% CI -5.12 to 14.17The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.003 (P-value is for Q2 - Month 9.) · Ls mean differences: 16.33 · 95% CI 5.68 to 26.98The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.212 (P-value is for Q2 - Month 9.) · Ls mean differences: 6.62 · 95% CI -3.80 to 17.04The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.461 (P-value is for Q2 - Month 10.5.) · Ls mean differences: 4.55 · 95% CI -7.58 to 16.68The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.835 (P-value is for Q2 - Month 10.5.) · Ls mean differences: -1.26 · 95% CI -13.16 to 10.63The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.030 (P-value is for Q2 - Month13.5.) · Ls mean differences: 13.36 · 95% CI 1.27 to 25.46The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.326 (P-value is for Q2 - Month13.5.) · Ls mean differences: 5.96 · 95% CI -5.97 to 17.89The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.019 (P-value is for Q3 - Month 9.) · Ls mean differences: 12.06 · 95% CI 1.98 to 22.15The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.621 (P-value is for Q3 - Month 9.) · Ls mean differences: 2.48 · 95% CI -7.38 to 12.35The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.968 (P-value is for Q3 - Month 10.5.) · Ls mean differences: 0.23 · 95% CI -11.03 to 11.49The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.327 (P-value is for Q3 - Month 10.5.) · Ls mean differences: -5.51 · 95% CI -16.55 to 5.54The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.066 (P-value is for Q3 - Month 13.5.) · Ls mean differences: 11.67 · 95% CI -0.76 to 24.09The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.415 (P-value is for Q3 - Month 13.5.) · Ls mean differences: 5.09 · 95% CI -7.17 to 17.34The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.011 (P-value is for Q4 - Month 9.) · Ls mean differences: 11.87 · 95% CI 2.79 to 20.94The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.394 (P-value is for Q4 - Month 9.) · Ls mean differences: 3.85 · 95% CI -5.03 to 12.72The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.684 (P-value is for Q4 - Month 10.5.) · Ls mean differences: -1.94 · 95% CI -11.28 to 7.41The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.126 (P-value is for Q4 - Month 10.5.) · Ls mean differences: -7.14 · 95% CI -16.30 to 2.02The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.061 (P-value is for Q4 - Month 13.5.) · Ls mean differences: 11.52 · 95% CI -0.53 to 23.57The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.403 (P-value is for Q4 - Month13.5.) · Ls mean differences: 5.06 · 95% CI -6.83 to 16.95The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.013 (P-value is for Q5 - Month 9.) · Ls mean differences: 11.38 · 95% CI 2.38 to 20.38The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.410 (P-value is for Q5 - Month 9.) · Ls mean differences: 3.69 · 95% CI -5.11 to 12.49The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.537 (P-value is for Q5 - Month 10.5.) · Ls mean differences: -2.85 · 95% CI -11.92 to 6.22The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.058 (P-value is for Q5 - Month 10.5.) · Ls mean differences: -8.59 · 95% CI -17.48 to 0.30The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.061 (P-value is for Q5 - Month 13.5.) · Ls mean differences: 11.44 · 95% CI -0.54 to 23.41The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.353 (P-value is for Q5 - Month 13.5.) · Ls mean differences: 5.59 · 95% CI -6.23 to 17.40The MMRM model included terms for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
SecondaryChange From Baseline in 'Yes' Answers to Morning Erections

The participants were asked to complete the morning erections diary every morning during the 4-week period before randomization and during the 6-week, Drug-Free, Washout Period. Data presented are the changes in the participant's percentage of "yes" responses relative to the number of days the question was answered during treatment. The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline morning erections frequency, age group and country.

Time frame:
Randomization (Baseline), Month 10.5
Reported as:
Least squares mean · percentage of "yes" response
Change From Baseline in 'Yes' Answers to Morning Erections
percentage of "yes" responseTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Change From Baseline in 'Yes' Answers to Morning Erections8.92 (1.45 to 16.39)12.16 (5.16 to 19.16)14.04 (6.74 to 21.35)
Statistical analysis
  • Tadalafil 5 mg OaD vs Placebo · ANCOVA · p = 0.162 · Ls mean differences: -5.12 · 95% CI -12.32 to 2.08ANCOVA model included treatment, baseline, age group, and country.
  • Tadalafil 20 mg PRN vs Placebo · ANCOVA · p = 0.603 · Ls mean differences: -1.88 · 95% CI -8.99 to 5.24ANCOVA model included treatment, baseline, age group, and country.
SecondaryStandardized Morning Erections Question (SMEQ) Score at Month 2

Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ ("Do you ever wake up with an erection") using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).

Time frame:
Month 2
Reported as:
Number · participants
Standardized Morning Erections Question (SMEQ) Score at Month 2
participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Yes, regularly477
Less frequently than in the past81510
Only occasionally413126
Never738087
Missing13911
SecondaryStandardized Morning Erections Question (SMEQ) Score at Month 9

Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ ("Do you ever wake up with an erection") using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).

Time frame:
Month 9
Reported as:
Number · participants
Standardized Morning Erections Question (SMEQ) Score at Month 9
participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Yes, regularly797
Less frequently than in the past21199
Only occasionally362627
Never396165
Missing1177
SecondaryStandardized Morning Erections Question (SMEQ) Score at Month 13.5

Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ ("Do you ever wake up with an erection") using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).

Time frame:
Month 13.5
Reported as:
Number · participants
Standardized Morning Erections Question (SMEQ) Score at Month 13.5
participantsTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Yes, regularly131513
Less frequently than in the past222418
Only occasionally313027
Never324042
Missing256
SecondaryChange From Baseline in 26-item Expanded Prostate Cancer Index Composite (EPIC-26) Questionnaire Score

EPIC-26 (participants) contains 26 items and 5 domains: Urinary Incontinence (Items 1-4), Urinary Irritative/Obstructive (Items 5-8), Bowel (Items 10-15), Sexual (Items 16-21), and Hormonal (Items 22-26). Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0 to 100 scale for each domain, with higher scores representing better health-related quality of life. Responses are based on experiences during the previous 4 weeks. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).

Time frame:
Randomization (Baseline), Months 9 and 13.5
Reported as:
Least squares mean · units on a scale
Change From Baseline in 26-item Expanded Prostate Cancer Index Composite (EPIC-26) Questionnaire Score
units on a scaleTadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Urinary Incontinence - Month 934.08 (29.31 to 38.86)31.12 (26.74 to 35.51)30.59 (25.85 to 35.33)
Urinary Incontinence - Month 13.537.41 (32.56 to 42.26)35.54 (31.10 to 39.97)35.44 (30.65 to 40.23)
Urinary Irritative/Obstructive - Month 913.83 (11.54 to 16.12)13.28 (11.19 to 15.37)12.26 (10.01 to 14.51)
Urinary Irritative/Obstructive - Month 13.513.86 (11.53 to 16.20)13.82 (11.70 to 15.94)12.30 (0.01 to 14.60)
Bowel - Month 95.94 (3.71 to 8.17)6.27 (4.22 to 8.33)6.48 (4.31 to 8.65)
Bowel - Month 13.56.87 (4.67 to 9.08)6.49 (4.46 to 8.52)6.78 (4.61 to 8.94)
Sexual - Month 927.53 (21.64 to 33.42)20.66 (15.27 to 26.06)17.98 (12.14 to 23.81)
Sexual - Month 13.536.55 (30.03 to 43.06)32.58 (26.60 to 38.56)33.37 (26.95 to 39.79)
Hormonal - Month 91.72 (-0.81 to 4.26)2.72 (0.36 to 5.08)-0.18 (-2.67 to 2.31)
Hormonal - Month 13.52.48 (0.10 to 4.87)2.92 (0.76 to 5.08)3.01 (0.67 to 5.36)
Statistical analysis
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.196 (P-value is for Urinary Incontinence - Month 9.) · Ls mean differences: 3.49 · 95% CI -1.82 to 8.80The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.841 (P-value is for Urinary Incontinence - Month 9.) · Ls mean differences: 0.53 · 95% CI -4.69 to 5.75The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.474 (P-value is for Urinary Incontinence - Month 13.5.) · Ls mean differences: 1.98 · 95% CI -3.45 to 7.40The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.971 (P-value is for Urinary Incontinence - Month 13.5.) · Ls mean differences: 0.10 · 95% CI -5.21 to 5.41The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.236 (P-value is for Urinary Irritative/Obstructive - Month 9.) · Ls mean differences: 1.57 · 95% CI -1.03 to 4.17The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.429 (P-value is for Urinary Irritative/Obstructive - Month 9.) · Ls mean differences: 1.02 · 95% CI -1.52 to 3.56The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.252 (P-value is for Urinary Irritative/Obstructive - Month 13.5.) · Ls mean differences: 1.56 · 95% CI -1.12 to 4.24The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.251 (P-value is for Urinary Irritative/Obstructive - Month 13.5.) · Ls mean differences: 1.52 · 95% CI -1.08 to 4.11The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.671 (P-value is for Bowel - Month 9.) · Ls mean differences: -0.54 · 95% CI -3.03 to 1.95The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.868 (P-value is for Bowel - Month 9.) · Ls mean differences: -0.21 · 95% CI -2.64 to 2.23The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.938 (P-value is for Bowel - Month 13.5.) · Ls mean differences: 0.10 · 95% CI -2.37 to 2.57The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.813 (P-value is for Bowel - Month 13.5.) · Ls mean differences: -0.29 · 95% CI -2.69 to 2.12The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.004 (P-value is for Sexual - Month 9.) · Ls mean differences: 9.55 · 95% CI 3.10 to 15.99The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.403 (P-value is for Sexual - Month 9.) · Ls mean differences: 2.69 · 95% CI -3.63 to 9.00The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.406 (P-value is for Sexual - Month 13.5.) · Ls mean differences: 3.18 · 95% CI -4.34 to 10.69The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.832 (P-value is for Sexual - Month 13.5.) · Ls mean differences: -0.79 · 95% CI -8.11 to 6.53The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.197 (P-value is for Hormonal - Month 9.) · Ls mean differences: 1.90 · 95% CI -0.99 to 4.79The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.045 (P-value is for Hormonal - Month 9.) · Ls mean differences: 2.89 · 95% CI 0.06 to 5.72The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 5 mg OaD vs Placebo · Mixed Models Analysis · p = 0.692 (P-value is for Hormonal - Month 13.5.) · Ls mean differences: -0.53 · 95% CI -3.16 to 2.10The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
  • Tadalafil 20 mg PRN vs Placebo · Mixed Models Analysis · p = 0.943 (P-value is for Hormonal - Month 13.5.) · Ls mean differences: -0.09 · 95% CI -2.65 to 2.46The MMRM model included baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
SecondaryChange in Penile Length and Girth

Measurements were performed with the penis in the flaccid state. The stretched penile length was measured from the tip of the glans to the pubopenile skin junction while applying tension to maximally stretch the penis. The penile circumference at midshaft was measured. All measurements were taken with a paper ruler to the nearest 0.5 centimeter (cm). The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline, age group and country.

Time frame:
Randomization (Baseline), Month 9
Reported as:
Least squares mean · millimeter (mm)
Change in Penile Length and Girth
millimeter (mm)Tadalafil 5 mg OaDTadalafil 20 mg PRNPlacebo
Length-1.53 (-5.54 to 2.47)-7.26 (-11.04 to -3.49)-5.73 (-9.68 to -1.78)
Girth0.03 (-3.09 to 3.15)0.82 (-2.11 to 3.75)-2.34 (-5.43 to 0.75)
Statistical analysis
  • Tadalafil 5 mg OaD vs Placebo · ANCOVA · p = 0.028 (P-value is for length.) · Ls mean differences: 4.20 · 95% CI 0.47 to 7.93ANCOVA model included terms for treatment, baseline, age group and country.
  • Tadalafil 20 mg PRN vs Placebo · ANCOVA · p = 0.413 (P-value is for length.) · Ls mean differences: -1.53 · 95% CI -5.20 to 2.14ANCOVA model included terms for treatment, baseline, age group and country.
  • Tadalafil 5 mg OaD vs Placebo · ANCOVA · p = 0.112 (P-value is for girth.) · Ls mean differences: 2.37 · 95% CI -0.55 to 5.30ANCOVA model included terms for treatment, baseline, age group and country.
  • Tadalafil 20 mg PRN vs Placebo · ANCOVA · p = 0.031 (P-value is for girth.) · Ls mean differences: 3.16 · 95% CI 0.29 to 6.03ANCOVA model included terms for treatment, baseline, age group and country.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Screen - BNSRP—6/583 (1%)114/583 (19.6%)
Tadalafil 5 mg OaD (Double-Blind Period/Washout Period)—2/139 (1.4%)50/139 (36%)
Tadalafil 20 mg PRN (Double-Blind Period/Washout Period)—3/143 (2.1%)52/143 (36.4%)
Placebo (Double-Blind Period/Washout Period)—10/141 (7.1%)40/141 (28.4%)
Tadalafil 5 mg OaD (Open-Label Period)—1/139 (0.7%)11/139 (7.9%)
Tadalfil 20 mg PRN (Open-Label Period)—1/143 (0.7%)18/143 (12.6%)
Placebo (Open-Label Period)—2/141 (1.4%)9/141 (6.4%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventScreen - BNSRPTadalafil 5 mg OaD (Double-Blind Period/Washout Period)Tadalafil 20 mg PRN (Double-Blind Period/Washout Period)Placebo (Double-Blind Period/Washout Period)Tadalafil 5 mg OaD (Open-Label Period)Tadalfil 20 mg PRN (Open-Label Period)Placebo (Open-Label Period)
SplenomegalyBlood and lymphatic system disorders0/5831/1390/1430/1410/1390/1430/141
PyrexiaGeneral disorders0/5831/1390/1430/1410/1390/1430/141
Drug hypersensitivityImmune system disorders0/5831/1390/1430/1410/1390/1430/141
Intentional overdoseInjury, poisoning and procedural complications0/5830/1390/1430/1411/1390/1430/141
Acute myocardial infarctionCardiac disorders0/5830/1390/1431/1410/1390/1430/141
Rectal haemorrhageGastrointestinal disorders0/5830/1390/1431/1410/1390/1430/141
Abdominal abscessInfections and infestations0/5830/1390/1431/1410/1390/1430/141
ErysipelasInfections and infestations0/5830/1390/1430/1410/1390/1431/141
OsteoarthritisMusculoskeletal and connective tissue disorders0/5830/1390/1431/1410/1390/1430/141
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/5830/1390/1431/1410/1390/1430/141
Most frequent other events
Showing 10 of 233
Most frequent other events
EventScreen - BNSRPTadalafil 5 mg OaD (Double-Blind Period/Washout Period)Tadalafil 20 mg PRN (Double-Blind Period/Washout Period)Placebo (Double-Blind Period/Washout Period)Tadalafil 5 mg OaD (Open-Label Period)Tadalfil 20 mg PRN (Open-Label Period)Placebo (Open-Label Period)
HeadacheNervous system disorders9/5835/13911/1436/1411/1392/1431/141
Urinary incontinenceRenal and urinary disorders34/5833/1390/1430/1410/1390/1430/141
Urinary tract infectionInfections and infestations21/5833/1394/1432/1411/1390/1430/141
DyspepsiaGastrointestinal disorders0/5835/1395/1431/1411/1391/1430/141
NasopharyngitisInfections and infestations2/5835/1395/1433/1410/1391/1430/141
Back painMusculoskeletal and connective tissue disorders1/5835/1395/1433/1410/1391/1431/141
MyalgiaMusculoskeletal and connective tissue disorders5/5835/1395/1431/1410/1390/1431/141
Seasonal allergyImmune system disorders0/5834/1390/1430/1410/1390/1430/141
Pain in extremityMusculoskeletal and connective tissue disorders2/5833/1394/1430/1410/1390/1431/141
Procedural painInjury, poisoning and procedural complications13/5830/1391/1431/1410/1390/1430/141

Baseline characteristics

All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Tadalafil 5 mg OaDTadalafil 20 mg PRNPlaceboTotal
Mean58.6 ± 5.0757.5 ± 5.9157.6 ± 5.6957.9 ± 5.58
Sex: Female, Male
Sex: Female, Male(Participants)Tadalafil 5 mg OaDTadalafil 20 mg PRNPlaceboTotal
Female0000
Male139143141423
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Tadalafil 5 mg OaDTadalafil 20 mg PRNPlaceboTotal
White137141138416
American Indian or Alaska Native0101
Asian0011
Black or African American2125
Region of Enrollment
Region of Enrollment(participants)Tadalafil 5 mg OaDTadalafil 20 mg PRNPlaceboTotal
France12131338
Canada13131238
Belgium79824
Poland109827
Spain383939116
Germany26252778
Netherlands0213
United Kingdom78823
Switzerland1113
Italy25242473
08

Study locations

52 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kortrijk, 8500, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leuven, 3000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Liège, 4000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calgary, Alberta T2W 1P9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Victoria, British Columbia V8T 5G1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, Ontario N6A 4V2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Creteil, 94010, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Grenoble, 38043, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon, 69437, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nice, 06002, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nimes, 30029, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pierre Benite, 69495, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 12203, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Braunschweig, 38126, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dresden, 01307, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Essen, 45122, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 20246, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hannover, 30625, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Herne, 44627, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leipzig, 04103, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leverkusen, 51375, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Acquavivadellefonti, 70021, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bergamo, 24128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bologna, 40138, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Genova, 16132, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Milano, 20132, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Perugia, 06122, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Amsterdam, 1066 CX, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leiden, 2300 RC, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nijmegen, 6532 SZ, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rotterdam, 3045 PM, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    S-Hertogenbosch, 5211 NL, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Veldhoven, 5504 DB, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bydgoszcz, 85-168, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdansk, 80-952, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kielce, 25-734, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 02-005, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zabrze, 41-800, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aravaca, 28023, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cordoba, 14004, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28046, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Majadahonda, 28222, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Málaga, 29010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 41013, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Valencia, 46010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Basel, CH-4031, Switzerland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Luzern, CH-6000, Switzerland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zurich, CH-8091, Switzerland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Middlesbrough, Cleveland TS4 3BW, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stevenage, Herts SG4 7NH, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Withington, Manchester M20 9BX, United Kingdom
09

References and documents

Publications

  • Montorsi F, Oelke M, Henneges C, Brock G, Salonia A, d'Anzeo G, Rossi A, Mulhall JP, Buttner H. Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy. Eur Urol. 2016 Sep;70(3):529-37. doi: 10.1016/j.eururo.2016.02.036. Epub 2016 Mar 3. PubMed 26947602 ↗
  • Patel HR, Ilo D, Shah N, Cuzin B, Chadwick D, Andrianne R, Henneges C, Barry J, Hell-Momeni K, Branicka J, Buttner H. Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV study. BMC Urol. 2015 Apr 12;15:31. doi: 10.1186/s12894-015-0022-9. PubMed 25879460 ↗
  • Montorsi F, Brock G, Stolzenburg JU, Mulhall J, Moncada I, Patel HR, Chevallier D, Krajka K, Henneges C, Dickson R, Buttner H. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). Eur Urol. 2014 Mar;65(3):587-96. doi: 10.1016/j.eururo.2013.09.051. Epub 2013 Oct 13. PubMed 24169081 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2009
First posted
Dec 4, 2009
Start
Nov 2009
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
Nov 14, 2013
Last update
Jan 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01026818
Responsible party
Sponsor
First posted
Dec 4, 2009
Start date
Nov 2009
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Nov 14, 2013
Last update
Jan 14, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion